110 HR 2875 IH: Medicare Residency Program Technical U.S. House of Representatives 2007-06-27 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I 110th CONGRESS 1st Session H. R. 2875 IN THE HOUSE OF REPRESENTATIVES June 27, 2007 Mr. Kagen (for himself, Mr. Kind, Mr. Ryan of Wisconsin, Mr. Obey, Ms. Baldwin, Ms. Moore of Wisconsin, Mr. Petri, and Mr. Sensenbrenner) introduced the following bill; which was referred to the Committee on Ways and Means A BILL To amend title XVIII of the Social Security Act to provide for a technical correction to the amendments made by section 422 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

1.

Short title

This Act may be cited as the Medicare Residency Program Technical Correction Act of 2007.

2.

Reinstatement of full-time equivalent resident slots that were erroneously eliminated

(a)

In general

Section 1886(h)(7) of the Social Security Act (42 U.S.C. 1395ww(h)(7)) is amended— (1)by redesignating subparagraph (D) as subparagraph (E); and (2)by inserting after subparagraph (C) the following new subparagraph: (D)

Adjustment based on settled cost report

In the case of a hospital for which— (i)the otherwise applicable resident limit was reduced under subparagraph (A)(i)(I); and (ii)such reduction was based on a reference resident level that was determined using a cost report that was subsequently settled, whether as a result of an appeal or otherwise, and the reference resident level under such settled cost report is higher than the level used for the reduction under subparagraph (A)(i)(I); the Secretary shall apply subparagraph (A)(i)(I) using the higher resident reference level and make any necessary adjustments to such reduction. Any such necessary adjustments shall be effective for portions of cost reporting periods occurring on or after July 1, 2005.. (b)

Effective date

The amendments made by this section shall take effect as if included in the enactment of section 422 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (Public Law 108–173).